Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nepal pilot aims to stop suicides in remote villages

NCT ID NCT07362056

Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a suicide prevention package (PSuPP) in rural Nepal's primary care clinics. Researchers will train healthcare workers to better identify and support people at risk of suicide. The pilot involves 147 participants and focuses on whether the program is practical and acceptable, not yet on whether it saves lives. Results will guide a future larger trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Suicide Prevention Package (PSuPP) - a set of training tools and protocols for healthcare workers
What this could lead to
If successful, this could pave the way for a larger study that may improve suicide risk detection and care in low-resource primary care settings.
What could go wrong
This is a small pilot study focused on feasibility, not effectiveness. The results may not apply to other regions or health systems, and the intervention may not reduce suicide rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 147 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Primary Care Providers * Health workers with a prescribing license employed in government health facilities in Bagmati Province. * Are between 21-65 years, per government health system criteria. * Participants will be required to have competency in Nepali, be actively engaged in care provision within their health facility Patients: * Patient lives in the study site * Is under the care of a PCP at a facility site. * Patient meets any level of suicide risk based on mhGAP 2.0 criteria. * Patients who have been treated for mental illness before or presently (expected in both groups). * Speaks Nepali. * Levels of Suicide Risk (as defined by mhGAP 2.0) Exclusion Criteria: Primary Care Providers * Healthcare workers without proper government credentials will be excluded. * Health workers who plan to migrate or who do not intend to stay in the study area for at least a year. Patients: * Patient requiring immediate hospitalization * Unable to consent as determined by the diminished capacity tool.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary care are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Suicide Suicide Prevention

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary care Suicide

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Primary care facilities

    RECRUITING

    Dolakhā, Nepal

More trials for these conditions

Other studies related to the condition(s) this trial covers.